Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Theoretical characterization of galanin receptor type 3 (Gal3 ) and its interaction with agonist (GALANIN) and antagonists (SNAP 37889 and SNAP 398299): an in silico analysis.

Kothandan G, Gadhe CG, Cho SJ.

Chem Biol Drug Des. 2013 Jun;81(6):757-74. doi: 10.1111/cbdd.12128. Epub 2013 Apr 17.

PMID:
23461969
2.

Determining receptor-ligand interaction of human galanin receptor type 3.

Runesson J, Sollenberg UE, Jurkowski W, Yazdi S, Eriksson EE, Elofsson A, Langel U.

Neurochem Int. 2010 Dec;57(7):804-11. doi: 10.1016/j.neuint.2010.08.018. Epub 2010 Sep 9.

PMID:
20817064
3.

Binding site analysis of CCR2 through in silico methodologies: docking, CoMFA, and CoMSIA.

Kothandan G, Gadhe CG, Madhavan T, Cho SJ.

Chem Biol Drug Des. 2011 Jul;78(1):161-74. doi: 10.1111/j.1747-0285.2011.01095.x. Epub 2011 Mar 29.

PMID:
21294847
4.

Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299.

Swanson CJ, Blackburn TP, Zhang X, Zheng K, Xu ZQ, Hökfelt T, Wolinsky TD, Konkel MJ, Chen H, Zhong H, Walker MW, Craig DA, Gerald CP, Branchek TA.

Proc Natl Acad Sci U S A. 2005 Nov 29;102(48):17489-94. Epub 2005 Nov 15. Erratum in: Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14978. Proc Natl Acad Sci U S A. 2006 Apr 4;103(14):5632.

5.

Studies of tricyclic piperazine/piperidine furnished molecules as novel integrin αvβ3/αIIbβ3 dual antagonists using 3D-QSAR and molecular docking.

Yan Y, Li Y, Zhang S, Ai C.

J Mol Graph Model. 2011 Feb;29(5):747-62. doi: 10.1016/j.jmgm.2010.12.008. Epub 2011 Jan 8.

PMID:
21273104
6.

Theoretical analysis of somatostatin receptor 5 with antagonists and agonists for the treatment of neuroendocrine tumors.

Nagarajan SK, Babu S, Madhavan T.

Mol Divers. 2017 May;21(2):367-384. doi: 10.1007/s11030-016-9722-7. Epub 2017 Feb 2.

PMID:
28155055
7.

3-arylimino-2-indolones are potent and selective galanin GAL3 receptor antagonists.

Konkel MJ, Lagu B, Boteju LW, Jimenez H, Noble S, Walker MW, Chandrasena G, Blackburn TP, Nikam SS, Wright JL, Kornberg BE, Gregory T, Pugsley TA, Akunne H, Zoski K, Wise LD.

J Med Chem. 2006 Jun 29;49(13):3757-8.

PMID:
16789730
8.

Amino substituted analogs of 1-phenyl-3-phenylimino-2-indolones with potent galanin Gal3 receptor binding affinity and improved solubility.

Konkel MJ, Packiarajan M, Chen H, Topiwala UP, Jimenez H, Talisman IJ, Coate H, Walker MW.

Bioorg Med Chem Lett. 2006 Aug 1;16(15):3950-4. Epub 2006 May 30.

PMID:
16730981
9.

Molecular docking and 3D QSAR studies on 1-amino-2-phenyl-4-(piperidin-1-yl)-butanes based on the structural modeling of human CCR5 receptor.

Xu Y, Liu H, Niu C, Luo C, Luo X, Shen J, Chen K, Jiang H.

Bioorg Med Chem. 2004 Dec 1;12(23):6193-208.

PMID:
15519163
10.

Ligand binding properties of human galanin receptors.

Jurkowski W, Yazdi S, Elofsson A.

Mol Membr Biol. 2013 Mar;30(2):206-16. doi: 10.3109/09687688.2012.750384. Epub 2012 Dec 13.

PMID:
23237663
11.

Evidence that the modulatory effect of galanin on inflammatory edema formation is mediated by the galanin receptor 3 in the murine microvasculature.

Schmidhuber SM, Rauch I, Kofler B, Brain SD.

J Mol Neurosci. 2009 Feb;37(2):177-81. doi: 10.1007/s12031-008-9135-x. Epub 2008 Aug 5.

PMID:
18679831
12.

Galanin (2-11) binds to GalR3 in transfected cell lines: limitations for pharmacological definition of receptor subtypes.

Lu X, Lundström L, Bartfai T.

Neuropeptides. 2005 Jun;39(3):165-7. Epub 2005 Feb 1.

PMID:
15944007
13.

Binding site exploration of CCR5 using in silico methodologies: a 3D-QSAR approach.

Gadhe CG, Kothandan G, Cho SJ.

Arch Pharm Res. 2013 Jan;36(1):6-31. doi: 10.1007/s12272-013-0001-1.

PMID:
23325486
14.

Docking and 3D-QSAR (quantitative structure activity relationship) studies of flavones, the potent inhibitors of p-glycoprotein targeting the nucleotide binding domain.

Kothandan G, Gadhe CG, Madhavan T, Choi CH, Cho SJ.

Eur J Med Chem. 2011 Sep;46(9):4078-88. doi: 10.1016/j.ejmech.2011.06.008. Epub 2011 Jul 1.

PMID:
21723648
15.
16.

In vitro toxicity of the galanin receptor 3 antagonist SNAP 37889.

Koller A, Rid R, Beyreis M, Bianchini R, Holub BS, Lang A, Locker F, Brodowicz B, Velickovic O, Jakab M, Kerschbaum H, Önder K, Kofler B.

Neuropeptides. 2016 Apr;56:83-8. doi: 10.1016/j.npep.2015.12.003. Epub 2015 Dec 8.

PMID:
26725588
17.

Exploring the structure determinants of pyrazinone derivatives as PDE5 3HC8 inhibitors: an in silico analysis.

Li Y, Wu W, Ren H, Wang J, Zhang S, Li G, Yang L.

J Mol Graph Model. 2012 Sep;38:112-22. doi: 10.1016/j.jmgm.2012.07.003. Epub 2012 Jul 16.

PMID:
23085160
18.

Molecular modeling of histamine H3 receptor and QSAR studies on arylbenzofuran derived H3 antagonists.

Dastmalchi S, Hamzeh-Mivehroud M, Ghafourian T, Hamzeiy H.

J Mol Graph Model. 2008 Jan;26(5):834-44. Epub 2007 May 16.

PMID:
17561422
19.

Identification of the binding sites of the SR49059 nonpeptide antagonist into the V1a vasopressin receptor using sulfydryl-reactive ligands and cysteine mutants as chemical sensors.

Tahtaoui C, Balestre MN, Klotz P, Rognan D, Barberis C, Mouillac B, Hibert M.

J Biol Chem. 2003 Oct 10;278(41):40010-9. Epub 2003 Jul 17.

20.

Exploration of a binding mode of indole amide analogues as potent histone deacetylase inhibitors and 3D-QSAR analyses.

Guo Y, Xiao J, Guo Z, Chu F, Cheng Y, Wu S.

Bioorg Med Chem. 2005 Sep 15;13(18):5424-34.

PMID:
15963726

Supplemental Content

Support Center